| Type 1 diabetes | Type 2 diabetes |
---|---|---|
Participants (n) | 2881 | 1823 |
Diabetes technology during lockdown | ||
 CGM (n) | 10 | – |
 FGM (n) | 5 | – |
 HCL (n) | 2 | – |
 SAP (n) | 1 | – |
 Different types (n) (CGM, CSII, FGM, insulin pump) | 5 | – |
 Telemedicinea (n) | – | 5 |
 Not described (n) | 2 | 3 |
Location | ||
 Italy (n) | 11 | 2 |
 Spain (n) | 6 | – |
 Turkey (n) | – | 2 |
 India (n) | 4 | 3 |
 Greece (n) | 1 | 1 |
 China (n) | 1 | – |
 Israel (n) | 1 | – |
 UK (n) | 2 | – |
 Saudi Arabia (n) | 1 | – |
 Japan (n) | 1 | – |
Outcomesb | ||
 Impact lockdown on HbA1c (%) pooled HbA1c levels | Mean difference − 0.05 (95% CI − 0.31 to 0.21) (based on n = 11 studies) | Mean difference + 0.14 (95% CI − 0.13 to 0.40) (based on n = 8 studies) |
Impact lockdown on time in range (TIR) (%), 70–180 mg/dl pooled TIR values | Mean difference + 3.75 (95% CI 2.56 to 4.92) (based on n = 18 studies) | N/A |